Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited t/a radpharm scientific - pentetic acid, quantity: 5 mg - injection, powder for - excipient ingredients: stannous chloride - indications as at 25 september 1996: technetium (99mtc) pentetate may be used as a renal perfusion imaging pharmaceutical.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diphtheria toxoid, quantity: 2 iu; pertussis filamentous haemagglutinin, quantity: 5 microgram; pertussis toxoid, quantity: 2.5 microgram; pertussis fimbriae 2 + 3, quantity: 5 microgram; pertactin, quantity: 3 microgram; tetanus toxoid, quantity: 20 iu - injection, suspension - excipient ingredients: glutaral; formaldehyde; phenoxyethanol; water for injections; aluminium phosphate - adacel is indicated for active immunisation against tetanus, diphtheria and pertussis in persons aged 10 years and over as a booster following primary immunisation. adacel may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - meningococcal polysaccharide group w135, quantity: 10 microgram; meningococcal polysaccharide group c, quantity: 10 microgram; meningococcal polysaccharide group a, quantity: 10 microgram; meningococcal polysaccharide group y, quantity: 10 microgram - injection, solution - excipient ingredients: sodium acetate; tetanus toxoid; sodium chloride; water for injections - menquadfi is indicated for active immunisation for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w and y.,the use of menquadfi should be in accordance with official recommendations.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

hameln pharmaceuticals - pentetate zinc trisodium (unii: nxu65ic8pg) (pentetic acid - unii:7a314hqm0i) - injection, solution, concentrate - 200 mg in 1 ml - zn-dtpa is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. none known.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

hameln pharmaceuticals - pentetate calcium trisodium (unii: g79yn26h5b) (pentetic acid - unii:7a314hqm0i) - injection, solution, concentrate - 200 mg in 1 ml - ca-dtpa is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. none known.

Armenia - Inggeris - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

wyeth pharmaceuticals - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal pol - suspension for injection - 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 4.4mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1

Armenia - Inggeris - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pfizer manufacturing belgium nv - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal pol - suspension for injection - 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 4.4mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 2 [iu] (lower fiducial limit); pertactin 2.5ug; pertussis filamentous haemagglutinin 8ug; pertussis toxoid, adsorbed 8ug; tetanus toxoid, adsorbed 20 [iu] (lower fiducial limit); diphtheria toxoid, adsorbed 2 [iu] (lower fiducial limit); pertactin 2.5ug; pertussis filamentous haemagglutinin 8ug; pertussis toxoid, adsorbed 8ug; tetanus toxoid, adsorbed 20 [iu] (lower fiducial limit) - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 2 [iu] (lower fiducial limit) pertactin 2.5ug pertussis filamentous haemagglutinin 8ug pertussis toxoid, adsorbed 8ug tetanus toxoid, adsorbed 20 [iu] (lower fiducial limit) excipient: aluminium hydroxide aluminium phosphate formaldehyde glycine phenoxyethanol polysorbate 80 sodium chloride water for injection active: diphtheria toxoid, adsorbed 2 [iu] (lower fiducial limit) pertactin 2.5ug pertussis filamentous haemagglutinin 8ug pertussis toxoid, adsorbed 8ug tetanus toxoid, adsorbed 20 [iu] (lower fiducial limit) excipient: aluminium hydroxide aluminium phosphate sodium chloride water for injection - boostrix is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals aged four years and older.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]);  ; influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]);  ; influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]);   - solution for injection - 10µg/15µg/15µg per dose - active: influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)])   influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)])   influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)])   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin sodium chloride water for injection

Israel - Inggeris - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn or 69 kda omp); pertussis toxoid vaccine; tetanus toxoid - suspension for injection - pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml; diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid vaccine 8 mcg / 0.5 ml; inactivated polio virus (ipv) type 3 32 du / 0.5 ml; inactivated polio virus (ipv) type 1 40 du / 0.5 ml; inactivated polio virus (ipv) type 2 8 du / 0.5 ml - bacterial and viral vaccines, combined - for booster vaccination against diphtheria, tetanus and pertusis and poliomyelitis of individuals from the age of three years onwards. the administration of boostrix polio should be based on official recommendations.